issues
October 2009
Download PDFTABLE OF CONTENTS
The
Derek G. Hennecke, MBA, continues with part 5 of this 6-part series covering unique strategies for building lasting competitive advantages.
Eligen Vitamin B12 & the SNAC Carrier for Oral Delivery
Nicholas J. Hart, MBA, indicates Sodium N-[8-(2-hydroxybenzoyl) Amino] Caprylate has recently been reviewed by an independent panel of scientists and will soon be available for use in the US in combination with nutrients added to food and dietary supplements to improve their bioavailability.
Dendritic Polyguanidilyated Translocators for Ocular Drug Delivery
Chandrasekar Durairaj, PhD, and Uday B. Kompella, PhD, describe a novel class of polyguanidilyated dendrimers capable of membrane translocation as well as drug solubilization and discuss their potential for enhancing ocular drug delivery.
Topical Regional Neuro-Affective (TRNA) Therapy: Novel Ground-Breaking Triptan Drug Delivery for Treating Migraines
Ronald Aung-Din, MD, explains how the current short-comings in triptan therapy for migraine may now be overcome by the concept of topical regional neuro-affective therapy.
Properties of Modified-Release Pellets Prepared by Hot-Melt Extrusion
Sandra U. Schilling and James W. McGinity, PhD, believe hot-melt extrusion to be an efficient and continuous method to produce pellets with modified-release properties providing sustained or delayed drug release in the gastrointestinal tract.
Clotrimazole Controlled-Release Chitosan Films for Local Delivery in Oral Candidiasis
Bhupendra G. Prajapati, MPharm, and Madhabhai M. Patel, PhD, design a formulation of chitosan film for oral mucosal delivery of CLZ to investigate swelling index, mechanical properties, bioadhesive strength, mucoadhesion time, in vitro drug release, and in vitro permeation.
Evonik Pharma Polymers: A Company in Transition
Drug Delivery Executive: Dr. Jean-Luc Herbeaux, Head of Business Line Pharma Polymers at Evonik Degussa Corporation, shares how Pharma Polymers is working with customers to meet drug delivery challenges in the global market.
Minimizing Cardiovascular Liabilities Throughout Drug Development
Alain Stricker-Krongrad, PhD, and Stephen Wilson explain how a number of assays are available to identify potential toxicities during the discovery process, which can minimize time and resources spent on compounds with cardiovascular risks.
Kinex Pharmaceuticals: Novel Targeted Oncology Therapies for a Variety of Tumors
Executive Summary: Allen Barnett, CEO of Kinex Pharmaceuticals, recently spoke about the opportunities and challenges presented by developing new cancer drugs employing novel mechanisms of action.
DEPARTMENTS
Market News & Trends
Excipient Update
Ultra-Pure Chitosan: Insight on New Non-Animal Sources for Use in Advanced Drug Delivery & Cell Therapy
Technology Showcase
COVER
FEATURES
